Günther, Gunar; Kuhns, Martin; Friesen, Inna (2023). [Update: Diagnostics and treatment of pulmonary tuberculosis]. Deutsche medizinische Wochenschrift, 148(19), pp. 1227-1235. Thieme 10.1055/a-1937-8337
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
a-1937-8337.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (406kB) | Request a copy |
Molecular diagnostic tools have changed the approach to the detection of Mycobacterium tuberculosis and associated drug-resistance substantially. PCR-based technologies allow a more rapid detection with higher diagnostic sensitivity in pulmonary and extrapulmonary specimens. However, a real point of care test, which needs minimal technical resources remains missing. Genome sequencing technologies are currently changing tuberculosis drug resistance testing, and for some questions are replacing phenotypic drug resistance testing, based on culture.New evidence on treatment for drug-sensitive tuberculosis allows shortening of treatment to 4 months, or in selected cases even to 2 months based on the use of fluoroquinolones, high dose rifamycins and newly developed TB medicines.Such developments will very likely simplify the management of tuberculosis, although prevention remains the most important pillar of any tuberculosis related public health strategy.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology |
UniBE Contributor: |
Günther, Gunar |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1439-4413 |
Publisher: |
Thieme |
Language: |
German |
Submitter: |
Heidi Lobsiger |
Date Deposited: |
18 Oct 2023 07:08 |
Last Modified: |
18 Oct 2023 07:17 |
Publisher DOI: |
10.1055/a-1937-8337 |
PubMed ID: |
37793615 |
BORIS DOI: |
10.48350/187258 |
URI: |
https://boris.unibe.ch/id/eprint/187258 |
Actions (login required)
 |
Edit item |